Following the success of the recent pharmacovigilance webinars delivered, Wainwright Associates are offering a webinar on An Introduction to Scientific …
Strategic marketing group Cello has expanded its healthcare portfolio with the acquisition of consultancy firm Red Kite. The move has …
The UK prime minister David Cameron has put forward five major changes to the government’s beleaguered Health and Social Care …

Oxford, UK-based gene therapy company Oxford BioMedica has appointed Dr Alex Lewis as director of corporate activities and strategy, and …

In an industry first Pfizer is to use mobile phone and web-based technology to collect study data for pharma’s first …
Roche has signed a deal to develop diagnostic tests for products in Merck’s oncology pipeline, in a bid to make …
One Nucleus is a new organisation formed from the merger of two of England’s regional networks – ERBI (Eastern Region …
The UK government is taking Servier to court for allegedly blocking generic versions of its blood pressure drug Perindopril from …
Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …
Merck & Co is to submit its oral investigational cancer drug ridaforolimus to European and US regulators later this year …
The Council of the European Union gave its backing to the new Directive on Falsified Medicines on May 27, setting …

Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …
Bayer has appointed Peter Müller as its new head of finance. Currently head of the corporate finance unit within the …

Spanish pharma company Almirall has appointed Daniel MartÃnez Carretero as its chief financial officer. In addition to Finance, Daniel will …

Roche’s vemurafenib has proven one of the stars of the ASCO cancer conference by increasing overall survival in skin cancer …
GlaxoSmithKline and Merck & Co have pledged to offer their rotavirus vaccines at discounted prices to developing countries. GSK is …
Prescribing a drug off-label when a licenced alternative exists increases patient safety risks and threatens the development of new medicines, …

Novartis’ Lucentis has been approved in Europe to treat people suffering from vision loss due to macular oedema secondary to …
SERVICE INSIGHTWhile everyone is going digital, are we forgetting the power of the spoken word? Some days it feels as …

The government’s six-week ‘pause’ in the passage of the controversial Health and Social Care Bill has now come to an …